Avid Bioservices Inc (CDMO)

[biopharm]

#7 #8 PS Targeting Patent - Roche BMS - also stepping on the patents(will have to update the complete list from prior post...)

PS Targeting patents with MOA of targeting flipped PS just may be the MOA of Roche in this patent....what happens first ? Target flipped PS which then results in tim-3 changes....etc

Also OX40 with BMS patents and Dr Jedd Wolchok has the answers where PS Targeting better than OX40 and when will CEO Roger Lias start backing up shareholders and fighting for the IP assets surrounding PS Targeting.
_____________

Publication number WO2016071448 A1
Publication type Application
Application number PCT/EP2015/075820
Publication date May 12, 2016
Filing date Nov 5, 2015
Priority date Nov 6, 2014
Also published as CA2964830A1, CN107001475A, EP3215532A1, US20160257749

Inventors

Valeria Lifke,
Guy Georges,
Victor LEVITSKY,
Oliver Ploettner,
Stefan Seeber,
Barbara Weiser,
Ildiko WUENSCHE,
Adrian ZWICK

Applicant
F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc.

https://www.google.com/patents/WO2016071448A1?cl=en

_______


Justia Patents Alan J. Korman Inventions, Patents and Patent Applications


Patents by Inventor Alan J. Korman
Alan J. Korman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

ANTIBODIES AGAINST TIM3 AND USES THEREOF
Publication number: 20180016336
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
Type: Application
Filed: July 13, 2017
Publication date: January 18, 2018
Applicant: Bristol-Myers Squibb Company
Inventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TROUNG
ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF
Publication number: 20180002432
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Type: Application
Filed: July 11, 2017
Publication date: January 4, 2018
Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla HENNING, Michelle Minhua HAN, Guodong CHEN, Richard HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan WONG, Huiming LI
ANTIBODIES AGAINST OX40 AND USES THEREOF
Publication number: 20170306035
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Type: Application
Filed: March 30, 2017
Publication date: October 26, 2017
Inventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Xiang SHAO, Mohan SRINIVASAN, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Patrick GUIRNALDA
ANTIBODIES AGAINST CD73
Publication number: 20170253665
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Type: Application
Filed: February 14, 2017
Publication date: September 7, 2017
Inventors: Nils LONBERG, Alan J. KORMAN, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Ming LEI, Emanuela SEGA, Angela GOODENOUGH, Maria N. JURE-KUNKEL, Guodong CHEN, John S. SACK, Richard HUANG, Martin J. CORBETT, Joseph E. MYERS, JR., Liang SCHWEIZER, Sandra V. HATCHER, Haichun HUANG, Pingping ZHANG
TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
Publication number: 20170247455
Abstract: This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to PD-1; and (b) an antibody or an antigen-binding portion thereof that specifically binds to CD137.
Type: Application
Filed: August 21, 2015
Publication date: August 31, 2017
Inventors: Maria JURE-KUNKEL, David M. Berman, Alan J. Korman, Mark J. Selby, Suba Krishnan
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
Patent number: 9745379
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Type: Grant
Filed: November 23, 2015
Date of Patent: August 29, 2017
Assignee: BRISTOL-MYERS SQUIBB COMPANY
Inventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
Publication number: 20170158767
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Type: Application
Filed: January 23, 2017
Publication date: June 8, 2017
Applicant: E.R. Squibb & Sons, L. L. C.
Inventors: Alan J. KORMAN, Mark J. SELBY, Changyu WANG, Mohan SRINIVASAN, David B. PASSMORE, Haichun HUANG, Haibin CHEN
ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF
Publication number: 20170145104
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Type: Application
Filed: December 5, 2016
Publication date: May 25, 2017
Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Guodong CHEN, Richard HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan WONG, Huiming LI
Antibodies against OX40 and uses thereof
Patent number: 9644032
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Type: Grant
Filed: May 26, 2016
Date of Patent: May 9, 2017
Assignee: BRISTOL-MYERS SQUIBB COMPANY
Inventors: Zhehong Cai, Indrani Chakraborty, Marie-Michelle Navarro Garcia, Thomas D. Kempe, Alan J. Korman, Alexander T. Kozhich, Hadia Lemar, Mark Maurer, Christina Maria Milburn, Michael Quigley, Xiang Shao, Mohan Srinivasan, Kent Thudium, Susan Chien-Szu Wong, Jochem Gokemeijer, Xi-Tao Wang, Han Chang, Patrick Guirnalda
Monoclonal Antibodies to Programmed Death 1 (PD-1)
Publication number: 20170088615
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Type: Application
Filed: October 7, 2016
Publication date: March 30, 2017
Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
Inventors: Alan J. KORMAN, Mohan SRINIVASAN, Changyu WANG, Mark J. SELBY, Bingliang CHEN, Josephine M. CARDARELLI, Haichun HUANG
Antibodies against CD73
Patent number: 9605080
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Type: Grant
Filed: January 13, 2016
Date of Patent: March 28, 2017
Assignee: BRISTOL-MYERS SQUIBB COMPANY
Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
Patent number: 9580505
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Type: Grant
Filed: July 23, 2015
Date of Patent: February 28, 2017
Assignee: E.R. Squibb & Sons, L. L. C.
Inventors: Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
Patent number: 9580507
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Type: Grant
Filed: June 21, 2016
Date of Patent: February 28, 2017
Assignee: E.R. Squibb & Sons, L. L. C.
Inventors: Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
Patent number: 9546216
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Type: Grant
Filed: July 23, 2015
Date of Patent: January 17, 2017
Assignee: E.R. Squibb & Sons, L. L. C.
Inventors: Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1)
Publication number: 20160362495
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically hind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Type: Application
Filed: June 21, 2016
Publication date: December 15, 2016
Applicant: E.R. Squibb & Sons, L. L. C.
Inventors: Alan J. KORMAN, Mark J. SELBY, Changyu WANG, Mohan SRINIVASAN, David B. PASSMORE, Haichun HUANG, Haibin CHEN
ANTIBODIES AGAINST OX40 AND USES THEREOF
Publication number: 20160347849
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Type: Application
Filed: May 26, 2016
Publication date: December 1, 2016
Inventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Maria RODRIGUEZ, Xiang SHAO, Mohan SRINIVASAN, Brenda L. STEVENS, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Christine HUANG, Maria JURE-KUNKEL, Zheng YANG, Yan FENG, Patrick GUIRNALDA, Nils LONBERG, Bryan C. BARNHART, Aaron P. YAMNIUK, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL, Praveen AANUR, Mark J. SELBY
Monoclonal antibodies to Programmed Death 1 (PD-1)
Patent number: 9492539
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Type: Grant
Filed: April 9, 2014
Date of Patent: November 15, 2016
Assignees: Ono Pharmaceutical Co., Ltd., E.R. Squibb & Sons, L.L.C.
Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
Methods for treating cancer using anti-PD-1 antibodies
Patent number: 9492540
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Type: Grant
Filed: May 6, 2014
Date of Patent: November 15, 2016
Assignees: Ono Pharmaceutical Co., Ltd., E.R. Squibb & Sons, L.L.C.
Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
HUMAN CTLA-4 ANTIBODIES AND THEIR USES
Publication number: 20160257753
Abstract: The presently subject matter provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
Type: Application
Filed: May 24, 2016
Publication date: September 8, 2016
Applicant: E.R. Squibb & Sons, L.L.C.
Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
FULLY HUMAN ANTIBODIES TO BTLA
Publication number: 20160222114
Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
Type: Application
Filed: April 14, 2016
Publication date: August 4, 2016
Inventors: Jennifer Marie MATARAZA, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark J. Selby, Timothy W. Sproul, Heidi N. Leblanc

https://patents.justia.com/inventor/alan-j-korman